We found that WGP β-glucan combined with PD-1/PD-L1–blocking antibodies could delay cancer aggression in a lung cancer mouse model and improve mPFS and mOS in patients with advanced cancer who had developed a tolerance to immunotherapy. Here, PDCD1 is linked to cancer.